Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2022-12-16 00:00:00 ET · period of report 2022-12-14 · accession 0001415889-22-012648 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-16 | 2022-12-14 | TBPH | Winningham Rick E | CEO, Dir | S - Sale | $11.19 | -50.0K | 1.35M | -4% | -$559.5K | |
| 2022-12-16 | 2022-12-13 | TBPH | Winningham Rick E | CEO, Dir | G - Gift | — | -9,000 | 1.40M | -0.6% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-12-14 | S | D | 50,000 | $11.19 | 1,350,797 | D | — | — | (F2) This transaction was executed in multiple trades at prices from $11.17 to $11.235 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Ordinary Shares | 2022-12-13 | G | D | 9,000 | — | 1,400,797 | D | — | — | (F1) Bona Fide Gift. No compensation was given to the donor for the gifting of shares. |